Mark Emberton is a professor of Interventional Oncology and Dean of the UCL Faculty of Medical Sciences.
He works as a clinician-scientist who combines practice-changing research with a state-of-the-art clinical practice that exploits many of the techniques and intervention that he was instrumental in developing. These areas include the use of MRI in the risk stratification of men with prostate cancer. He was the earliest to adopt this technique. It is now becoming a global standard of care. His expertise in MRI drove the transition to image-directed prostate biopsy (that aims to reduce the burden of biopsy) and image-directed treatments (that aim to reduce the side-effects of treatment). Mark has led most of the studies that led to the use of technologies capable of preserving prostate tissue. These comprise High Intensity Focussed Ultrasound, Nanoknife electroporation and TookadTM Vascular targeted phototherapy.
He continues his research programme that now focuses on early detection of cancer and completely new ways of treating cancer. He holds a number of major grants and has published over 400 academic articles in many of the leading scientific journals.
He lectures widely, educates and trains the next generation of doctors and urologists, works with many charities and philanthropists to raise money for medical research and holds numerous leadership and advisory positions.